MARKET

OBLN

OBLN

Obalon
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.630
-0.070
-4.12%
Opening 12:16 01/15 EST
OPEN
1.670
PREV CLOSE
1.700
HIGH
1.700
LOW
1.580
VOLUME
140.03K
TURNOVER
--
52 WEEK HIGH
3.130
52 WEEK LOW
0.6200
MARKET CAP
12.67M
P/E (TTM)
-0.7910
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Learning Caution In A Volatile December
As we approach the final trading days of the year, it seems as though the market is going to spend the remaining days of 2020 fighting with itself, which seems appropriate for the year. My own experience this past week has been pretty similar, I feel like I'm fighting with myself and going from one extreme to the next.
Benzinga · 12/14/2020 14:37
STMicroelectronics, FireEye leads premarket losers' pack
Atossa Therapeutics (ATOS) -42% on announcing pricing of $20M underwritten public offering.Pluristem Therapeutics (PSTI) -42% after DMC recommendation following interim analysis of its Phase III CLI study.Photronics PLAB -18% on Q4 earnings release.Talos Energy
Seekingalpha · 12/09/2020 13:40
Global Intragastric Balloon Market Report 2020: Short Recovery Time has Resulted in the Rising Adoption of Intragastric Balloon Implantation
, /PRNewswire/ -- The report has been added to offering.
PR Newswire - PRF · 12/09/2020 11:45
IBIO, SFIX, ARCT and LXRX among midday movers
Gainers: Curis (CRIS) +335%.Lexicon Pharmaceuticals (LXRX) +97%.Mammoth Energy Services (TUSK) +61%.NeuroMetrix (NURO) +49%.Stitch Fix (SFIX) +45%.IGM Biosciences (IGMS) +38%.Blonder Tongue Laboratories (BDR) +26%.Infinity Pharmaceuticals (INFI) +25%.KLX Energy Services (KLXE) +24%.Contura Energy (CTRA)
Seekingalpha · 12/08/2020 17:40
Curis, Lexicon Pharmaceuticals leads healthcare gainers; Obalon Therapeutics, Arcturus Therapeutics among major losers
Gainers: Curis CRIS +333%, Lexicon Pharmaceuticals LXRX +78%, NeuroMetrix (NURO) +73%,  Cancer Genetics, Inc. (CGIX) +25%, Cantel Medical CMD +17%.Losers: Obalon Therapeutics (OBLN) -19%, Arcturus Therapeutics Holdings ARCT -16%, Agios Pharmaceuticals, Inc. (AGIO) -15%, iBio IBIO -15%, Trillium Therapeutics TRIL -14%.
Seekingalpha · 12/08/2020 16:00
Mid-Morning Market Update: Markets Edge Lower; AutoZone Earnings Top Estimates
Following the market opening Tuesday, the Dow traded down 0.10% to 30,040.36 while the NASDAQ fell 0.24% to 12,490.14. The S&P also fell, dropping 0.16% to 3,686.22.
Benzinga · 12/08/2020 15:12
GrowGeneration, Trillium Therapeutics leads premarket losers' pack
Meten EdtechX Education Group (METX) -23% on temporary offer allowing warrants to be exercised at a reduced price of $1.40 per share.Obalon Therapeutics (OBLN) -16%.Francesca's Holdings (FRAN) -13% on notice of delisting
Seekingalpha · 12/08/2020 13:22
The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 7)
Benzinga · 12/08/2020 13:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OBLN. Analyze the recent business situations of Obalon through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OBLN stock price target is 0.7500 with a high estimate of 0.7500 and a low estimate of 0.7500.
EPS
Institutional Holdings
Institutions: 38
Institutional Holdings: 2.59M
% Owned: 33.33%
Shares Outstanding: 7.77M
TypeInstitutionsShares
Increased
2
742.66K
New
5
765.85K
Decreased
2
14.95K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.13%
Healthcare Equipment & Supplies
-0.03%
Key Executives
Non-Executive Chairman/Independent Director
Kim Kamdar
President/Chief Executive Officer/Director
Andrew Rasdal
Chief Financial Officer
Nooshin Hussainy
Vice President
Donald Young
Other
Robert MacDonald
Vice President
Todd Wood
Director
William Plovanic
Independent Director
Raymond Dittamore
Independent Director
Douglas Fisher
Independent Director
Lesley Howe
Independent Director
Sharon Stevenson
Other
Bob MacDonald
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OBLN
Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Obalon Therapeutics Inc stock information, including NASDAQ:OBLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OBLN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OBLN stock methods without spending real money on the virtual paper trading platform.